机译:平衡血管生成调节因子以特定阶段的方式控制癌症进展和存活率
Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215;
Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215;
Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, CA 94143;
Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215;
Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215;
Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215;
Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215;
Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215;
Department of Medical Biochemistry and Microbiology, Uppsala University,75105 Uppsala, Sweden,Howard Hughes Medical Institute, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139;
Department of Biochemistry, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan;
Department of Biochemistry, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan;
Division of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215;
Howard Hughes Medical Institute, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139;
Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, CA 94143;
Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215,Harvard-MIT Division of Health Sciences and Technology,Boston, MA 02215;
机译:晚期胆道癌生存率与无进展生存期,缓解率和疾病控制率的相关性:一线化疗随机试验的荟萃分析
机译:评估晚期大肠癌治疗策略的替代终点:评估无进展生存期,疾病控制持续时间和策略失败时间-Aide等人的《癌症研究》小组的研究。
机译:通过疾病控制率在第8周预测总体生存或无进展生存与种族无关:西方与中国患有一线非小细胞肺癌的患者(接受或不接受贝伐单抗联合化疗)
机译:缺氧诱导因子-la和CD34作为血管生成因子在膀胱癌中的研究
机译:抗血管生成癌治疗的策略:利用血管内皮生长因子(VEGF)在肿瘤生长和内皮细胞存活中的作用。
机译:平衡血管生成调节因子以特定阶段的方式控制癌症进展和存活率
机译:平衡血管生成调节因子以特定阶段的方式控制癌症进展和存活率